Using basic science to design a clinical trial: Baseline characteristics of women enrolled in the kronos early estrogen prevention study (KEEPS)

Virginia M Miller, D. M. Black, E. A. Brinton, M. J. Budoff, M. I. Cedars, H. N. Hodis, R. A. Lobo, J. E. Manson, G. R. Merriam, F. Naftolin, N. Santoro, H. S. Taylor, S. M. Harman

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Observational and epidemiological studies suggest that menopausal hormone therapy (MHT) reduces cardiovascular disease (CVD) risk. However, results from prospective trials showed neutral or adverse effects most likely due to differences in participant demographics, such as age, timing of initiation of treatment, and preexisting cardiovascular disease, which reflected in part the lack of basic science information on mechanisms of action of hormones on the vasculature at the time clinical trials were designed. The Kronos Early Estrogen Replacement Study (KEEPS) is a prospective, randomized, controlled trial designed, using findings from basic science studies, to test the hypothesis that MHT when initiated early in menopause reduces progression of atherosclerosis. KEEPS participants are younger, healthier, and within 3 years of menopause thus matching more closely demographics of women in prior observational and epidemiological studies than women in the Women's Health Initiative hormone trials. KEEPS will provide information relevant to the critical timing hypothesis for MHT use in reducing risk for CVD.

Original languageEnglish (US)
Pages (from-to)228-239
Number of pages12
JournalJournal of Cardiovascular Translational Research
Volume2
Issue number3
DOIs
StatePublished - Sep 2009

Fingerprint

Estrogens
Clinical Trials
Hormones
Cardiovascular Diseases
Menopause
Observational Studies
Epidemiologic Studies
Information Science
Demography
Preexisting Condition Coverage
Estrogen Replacement Therapy
Women's Health
Therapeutics
Atherosclerosis
Healthy Volunteers
Randomized Controlled Trials

Keywords

  • Conjugated Equine Estrogen
  • Hormone Treatment
  • Menopause
  • Timing Hypothesis
  • Women's Health Initiative

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Genetics
  • Genetics(clinical)
  • Molecular Medicine
  • Pharmaceutical Science

Cite this

Using basic science to design a clinical trial : Baseline characteristics of women enrolled in the kronos early estrogen prevention study (KEEPS). / Miller, Virginia M; Black, D. M.; Brinton, E. A.; Budoff, M. J.; Cedars, M. I.; Hodis, H. N.; Lobo, R. A.; Manson, J. E.; Merriam, G. R.; Naftolin, F.; Santoro, N.; Taylor, H. S.; Harman, S. M.

In: Journal of Cardiovascular Translational Research, Vol. 2, No. 3, 09.2009, p. 228-239.

Research output: Contribution to journalArticle

Miller, VM, Black, DM, Brinton, EA, Budoff, MJ, Cedars, MI, Hodis, HN, Lobo, RA, Manson, JE, Merriam, GR, Naftolin, F, Santoro, N, Taylor, HS & Harman, SM 2009, 'Using basic science to design a clinical trial: Baseline characteristics of women enrolled in the kronos early estrogen prevention study (KEEPS)', Journal of Cardiovascular Translational Research, vol. 2, no. 3, pp. 228-239. https://doi.org/10.1007/s12265-009-9104-y
Miller, Virginia M ; Black, D. M. ; Brinton, E. A. ; Budoff, M. J. ; Cedars, M. I. ; Hodis, H. N. ; Lobo, R. A. ; Manson, J. E. ; Merriam, G. R. ; Naftolin, F. ; Santoro, N. ; Taylor, H. S. ; Harman, S. M. / Using basic science to design a clinical trial : Baseline characteristics of women enrolled in the kronos early estrogen prevention study (KEEPS). In: Journal of Cardiovascular Translational Research. 2009 ; Vol. 2, No. 3. pp. 228-239.
@article{708f667b67dc42e8b26bfae98226daff,
title = "Using basic science to design a clinical trial: Baseline characteristics of women enrolled in the kronos early estrogen prevention study (KEEPS)",
abstract = "Observational and epidemiological studies suggest that menopausal hormone therapy (MHT) reduces cardiovascular disease (CVD) risk. However, results from prospective trials showed neutral or adverse effects most likely due to differences in participant demographics, such as age, timing of initiation of treatment, and preexisting cardiovascular disease, which reflected in part the lack of basic science information on mechanisms of action of hormones on the vasculature at the time clinical trials were designed. The Kronos Early Estrogen Replacement Study (KEEPS) is a prospective, randomized, controlled trial designed, using findings from basic science studies, to test the hypothesis that MHT when initiated early in menopause reduces progression of atherosclerosis. KEEPS participants are younger, healthier, and within 3 years of menopause thus matching more closely demographics of women in prior observational and epidemiological studies than women in the Women's Health Initiative hormone trials. KEEPS will provide information relevant to the critical timing hypothesis for MHT use in reducing risk for CVD.",
keywords = "Conjugated Equine Estrogen, Hormone Treatment, Menopause, Timing Hypothesis, Women's Health Initiative",
author = "Miller, {Virginia M} and Black, {D. M.} and Brinton, {E. A.} and Budoff, {M. J.} and Cedars, {M. I.} and Hodis, {H. N.} and Lobo, {R. A.} and Manson, {J. E.} and Merriam, {G. R.} and F. Naftolin and N. Santoro and Taylor, {H. S.} and Harman, {S. M.}",
year = "2009",
month = "9",
doi = "10.1007/s12265-009-9104-y",
language = "English (US)",
volume = "2",
pages = "228--239",
journal = "Journal of Cardiovascular Translational Research",
issn = "1937-5387",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Using basic science to design a clinical trial

T2 - Baseline characteristics of women enrolled in the kronos early estrogen prevention study (KEEPS)

AU - Miller, Virginia M

AU - Black, D. M.

AU - Brinton, E. A.

AU - Budoff, M. J.

AU - Cedars, M. I.

AU - Hodis, H. N.

AU - Lobo, R. A.

AU - Manson, J. E.

AU - Merriam, G. R.

AU - Naftolin, F.

AU - Santoro, N.

AU - Taylor, H. S.

AU - Harman, S. M.

PY - 2009/9

Y1 - 2009/9

N2 - Observational and epidemiological studies suggest that menopausal hormone therapy (MHT) reduces cardiovascular disease (CVD) risk. However, results from prospective trials showed neutral or adverse effects most likely due to differences in participant demographics, such as age, timing of initiation of treatment, and preexisting cardiovascular disease, which reflected in part the lack of basic science information on mechanisms of action of hormones on the vasculature at the time clinical trials were designed. The Kronos Early Estrogen Replacement Study (KEEPS) is a prospective, randomized, controlled trial designed, using findings from basic science studies, to test the hypothesis that MHT when initiated early in menopause reduces progression of atherosclerosis. KEEPS participants are younger, healthier, and within 3 years of menopause thus matching more closely demographics of women in prior observational and epidemiological studies than women in the Women's Health Initiative hormone trials. KEEPS will provide information relevant to the critical timing hypothesis for MHT use in reducing risk for CVD.

AB - Observational and epidemiological studies suggest that menopausal hormone therapy (MHT) reduces cardiovascular disease (CVD) risk. However, results from prospective trials showed neutral or adverse effects most likely due to differences in participant demographics, such as age, timing of initiation of treatment, and preexisting cardiovascular disease, which reflected in part the lack of basic science information on mechanisms of action of hormones on the vasculature at the time clinical trials were designed. The Kronos Early Estrogen Replacement Study (KEEPS) is a prospective, randomized, controlled trial designed, using findings from basic science studies, to test the hypothesis that MHT when initiated early in menopause reduces progression of atherosclerosis. KEEPS participants are younger, healthier, and within 3 years of menopause thus matching more closely demographics of women in prior observational and epidemiological studies than women in the Women's Health Initiative hormone trials. KEEPS will provide information relevant to the critical timing hypothesis for MHT use in reducing risk for CVD.

KW - Conjugated Equine Estrogen

KW - Hormone Treatment

KW - Menopause

KW - Timing Hypothesis

KW - Women's Health Initiative

UR - http://www.scopus.com/inward/record.url?scp=68749108089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68749108089&partnerID=8YFLogxK

U2 - 10.1007/s12265-009-9104-y

DO - 10.1007/s12265-009-9104-y

M3 - Article

C2 - 19668346

AN - SCOPUS:68749108089

VL - 2

SP - 228

EP - 239

JO - Journal of Cardiovascular Translational Research

JF - Journal of Cardiovascular Translational Research

SN - 1937-5387

IS - 3

ER -